Role of the endothelium in pulmonary arterial hypertension

Vascular Pharmacology

Volumn 45, Issue 5, 2006, Pages 317-325

  Haworth, S G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

BMPR; Endothelium; Newborn; Pulmonary article hypertension

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; ARGININE; BONE MORPHOGENETIC PROTEIN RECEPTOR; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; FENFLURAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METALLOPROTEINASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PRAZIQUANTEL; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E2; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; THROMBOXANE RECEPTOR BLOCKING AGENT; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASODILATOR AGENT;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG TARGETING; EISENMENGER COMPLEX; ENDOTHELIUM CELL; EXTRACORPOREAL CIRCULATION; GENETIC ASSOCIATION; HEART CATHETERIZATION; HUMAN; INCIDENCE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SCHISTOSOMIASIS; SEX DIFFERENCE; SICKLE CELL ANEMIA; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; PULMONARY ARTERY; WORLD HEALTH;

EID: 33751075758     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.08.006     Document Type: Article

References (92)

1. Abman S.H., Chatfield B.A., Hall S.L., and McMurtry I.F. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am. J. Physiol. 259 (1990) H1921-H1927
2. Adatia I., Barrow S.E., Stratton P.D., Miall-Allen V.M., Ritter J.M., and Haworth S.G. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 88 (1993) 2117-2122
3. Adatia I., Barrow S.E., Stratton P.D., Ritter J.M., and Haworth S.G. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br. Heart J. 72 (1994) 452-456
4. Angdin M., and Settergren G. Acetylcholine reactivity in the pulmonary artery during cardiac surgery in patients with ischemic or valvular heart disease. J. Cardiothorac. Vasc. Anesth. 11 (1997) 458-462
5. Arrigoni F.I., Hislop A.A., Haworth S.G., and Mitchell J.A. Newborn intrapulmonary veins are more reactive than arteries in normal and hypertensive piglets. Am. J. Physiol. 277 (1999) L887-L892
6. Arrigoni F.I., Hislop A.A., Pollock J.S., Haworth S.G., and Mitchell J.A. Birth upregulates nitric oxide synthase activity in the porcine lung. Life Sci. 70 (2002) 1609-1620
7. Arrigoni F.I., Vallance P., Haworth S.G., and Leiper J.M. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107 (2003) 1195-1201
8. Atkinson C., Stewart S., Upton P.D., Machado R., Thomson J.R., Trembath R.C., and Morrell N.W. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105 (2002) 1672-1678
9. Badesch D.B., Orton E.C., Zapp L.M., Westcott J.Y., Hester J., Voelkel N.F., and Stenmark K.R. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 1 (1989) 489-498
10. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
11. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., Groves B.M., Tapson V.F., Bourge R.C., and Brundage B.H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334 (1996) 296-302
12. Bhat G.B., and Block E.R. Hypoxia directly increases serotonin transport by porcine pulmonary artery endothelial cell plasma membrane vesicles. Am. J. Respir. Cell Mol. Biol. 3 (1990) 363-367
13. Birukov K.G., Birukova A.A., Dudek S.M., Verin A.D., Crow M.T., Zhan X., DePaola N., and Garcia J.G. Shear stress-mediated cytoskeletal remodeling and cortactin translocation in pulmonary endothelial cells. Am. J. Respir. Cell Mol. Biol. 26 (2002) 453-464
14. Bloomfield G.L., Holloway S., Ridings P.C., Fisher B.J., Blocher C.R., Sholley M., Bunch T., Sugerman H.J., and Fowler A.A. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit. Care Med. 25 (1997) 584-593
15. Boels P.J., Deutsch J., Gao B., and Haworth S.G. Maturation of the response to bradykinin in resistance and conduit pulmonary arteries. Cardiovasc. Res. 44 (1999) 416-428
16. Celermajer D.S., Cullen S., and Deanfield J.E. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 87 (1993) 440-446
17. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., and Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327 (1992) 70-75
18. Cowan K.N., Jones P.L., and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 105 (2000) 21-34
19. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Kernis J.T. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115 (1991) 343-349
20. Daliento L., Somerville J., Presbitero P., Menti L., Brach-Prever S., Rizzoli G., and Stone S. Eisenmenger syndrome. Factors relating to deterioration and death. Eur. Heart J. 19 (1998) 1845-1855
21. de Cleva R., Herman P., Pugliese V., Zilberstein B., Saad W.A., Rodrigues J.J., and Laudanna A.A. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis-prospective study. Hepatogastroenterology 50 (2003) 2028-2030
22. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., Rutten H., Fichtlscherer S., Martin H., and Zeiher A.M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
23. Eddahibi S., Adnot S., Carville C., Blouquit Y., and Raffestin B. l-arginine restores endothelium-dependent relaxation in pulmonary circulation of chronically hypoxic rats. Am. J. Physiol. 263 (1992) L194-L200
24. Eddahibi S., Chaouat A., Morrell N., Fadel E., Fuhrman C., Bugnet A.S., Dartevelle P., Housset B., Hamon M., Weitzenblum E., and Adnot S. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108 (2003) 1839-1844
25. Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., Simonneau G., Dartevelle P., Hamon M., and Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108 (2001) 1141-1150
26. Fineman J.R., Chang R., and Soifer S.J. EDRF inhibition augments pulmonary hypertension in intact newborn lambs. Am. J. Physiol. 262 (1992) H1365-H1371
27. Foletta V.C., Lim M.A., Soosairajah J., Kelly A.P., Stanley E.G., Shannon M., He W., Das S., Massague J., and Bernard O. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J. Cell Biol. 162 (2003) 1089-1098
28. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
29. Garat C., Meignan M., Matthay M.A., Luo D.F., and Jayr C. Alveolar epithelial fluid clearance mechanisms are intact after moderate hyperoxic lung injury in rats. Chest 111 (1997) 1381-1388
30. Garcia J.G., Liu F., Verin A.D., Birukova A., Dechert M.A., Gerthoffer W.T., Bamberg J.R., and English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108 (2001) 689-701
31. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., and Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328 (1993) 1732-1739
32. Gimbrone Jr. M.A., Anderson K.R., Topper J.N., Langille B.L., Clowes A.W., Bercel S., Davies M.G., Stenmark K.R., Frid M.G., Weiser-Evans M.C., Aldashev A.A., Nemenoff R.A., Majesky M.W., Landerholm T.E., Lu J., Ito W.D., Arras M., Scholz D., Imhof B., Aurrand-Lions M., Schaper W., Nagel T.E., Resnick N., Dewey C.F., Gimbrone M.A., and Davies P.F. Special communication. The critical role of mechanical forces in blood vessel development, physiology and pathology. J. Vasc. Surg. 29 (1999) 1104-1151
33. Hall S.M., and Haworth S.G. Onset and evolution of pulmonary vascular disease in young children: abnormal postnatal remodelling studied in lung biopsies. J. Pathol. 166 (1992) 183-193
34. Hall S.M., Hislop A.A., Pierce C.M., and Haworth S.G. Prenatal origins of human intrapulmonary arteries: formation and smooth muscle maturation. Am. J. Respir. Cell Mol. Biol. 23 (2000) 194-203
35. Harrison R.E., Berger R., Haworth S.G., Tulloh R., Mache C.J., Morrell N.W., Aldred M.A., and Trembath R.C. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111 (2005) 435-441
36. Haworth S.G., and Hall S.M. Occlusion of intra-acinar pulmonary arteries in pulmonary hypertensive congenital heart disease. Int. J. Cardiol. 13 (1986) 207-217
37. Haworth S.G., Hall S.M., Chew M., and Allen K. Thinning of fetal pulmonary arterial wall and postnatal remodelling: ultrastructural studies on the respiratory unit arteries of the pig. Virchows Arch., A Pathol. Anat. Histopathol. 411 (1987) 161-171
38. Heath D., Helmholz Jr. H.F., Burchell H.B., Dushane J.W., and Edwards J.E. Graded pulmonary vascular changes and hemodynamic findings in cases of atrial and ventricular septal defect and patent ductus arteriosus. Circulation 18 (1958) 1155-1166
39. Herve P., Launay J.M., Scrobohaci M.L., Brenot F., Simonneau G., Petitpretz P., Poubeau P., Cerrina J., Duroux P., and Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99 (1995) 249-254
40. Hiramatsu T., Imai Y., Takanashi Y., Hoshino S., Yashima M., Tanaka S.A., Chang D., and Nakazawa M. Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. Ann. Thorac. Surg. 63 (1997) 648-652
41. Hislop A.A., Mak J.C., Reader J.A., Barnes P.J., and Haworth S.G. Muscarinic receptor subtypes in the porcine lung during postnatal development. Eur. J. Pharmacol. 359 (1998) 211-221
42. Hislop A.A., Springall D.R., Buttery L.D., Pollock J.S., and Haworth S.G. Abundance of endothelial nitric oxide synthase in newborn intrapulmonary arteries. Arch. Dis. Child., Fetal Neonatal Ed. 73 (1995) F17-F21
43. Hislop A.A., Zhao Y.D., Springall D.R., Polak J.M., and Haworth S.G. Postnatal changes in endothelin-1 binding in porcine pulmonary vessels and airways. Am. J. Respir. Cell Mol. Biol. 12 (1995) 557-566
44. Hislop A.A., Springall D.R., Oliveira H., Pollock J.S., Polak J.M., and Haworth S.G. Endothelial nitric oxide synthase in hypoxic newborn porcine pulmonary vessels. Arch. Dis. Child., Fetal Neonatal Ed. 77 (1997) F16-F22
45. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F., and Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (2004) 13S-24S
46. Keegan A., Morecroft I., Smillie D., Hicks M.N., and MacLean M.R. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ. Res. 89 (2001) 1231-1239
47. Kirshbom P.M., Jacobs M.T., Tsui S.S., DiBernardo L.R., Schwinn D.A., Ungerleider R.M., and Gaynor J.W. Effects of cardiopulmonary bypass and circulatory arrest on endothelium-dependent vasodilation in the lung. J. Thorac. Cardiovasc. Surg. 111 (1996) 1248-1256
48. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res. 47 (2000) 648-657
49. Komai H., and Haworth S.G. Thrombomodulin and angiotensin-converting enzyme activity during pediatric open heart operations. Ann. Thorac. Surg. 62 (1996) 553-558
50. Komai H., Adatia I.T., Elliott M.J., de Leval M.R., and Haworth S.G. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J. Thorac. Cardiovasc. Surg. 106 (1993) 473-478
51. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000) 1004-1010
52. Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips III J.A., Loyd J.E., Nichols W.C., and Trembath R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 26 (2000) 81-84
53. Langleben D., Christman B.W., Barst R.J., Dias V.C., Galie N., Higenbottam T.W., Kneussl M., Korducki L., Naeije R., Riedel A., Simonneau G., Hirsch A.M., Rich S., Robbins I.M., Oudiz R., McGoon M.D., Badesch D.B., Levy R.D., Mehta S., Seeger W., and Soler M. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am. Heart J. 143 (2002) E4
54. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272 (1997) 31725-31729
55. Launay J.M., Herve P., Peoc'h K., Tournois C., Callebert J., Nebigil C.G., Etienne N., Drouet L., Humbert M., Simonneau G., and Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8 (2002) 1129-1135
56. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., and Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Invest. 101 (1998) 927-934
57. Liu S.F., Hislop A.A., Haworth S.G., and Barnes P.J. Developmental changes in endothelium-dependent pulmonary vasodilatation in pigs. Br. J. Pharmacol. 106 (1992) 324-330
58. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., Whitley G.S., and Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119 (1996) 1533-1540
59. Machado R.F., and Gladwin M.T. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br. J. Haematol. 129 (2005) 449-464
60. Marcos E., Adnot S., Pham M.H., Nosjean A., Raffestin B., Hamon M., and Eddahibi S. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 168 (2003) 487-493
61. Matsumoto N., Manabe H., Ochiai J., Fujita N., Takagi T., Uemura M., Naito Y., Yoshida N., Oka S., and Yoshikawa T. An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity. Shock 19 (2003) 547-552
62. McDonald D.M., Thurston G., and Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 6 (1999) 7-22
63. McLaughlin V.V., Presberg K.W., Doyle R.L., Abman S.H., McCrory D.C., Fortin T., and Ahearn G. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 78S-92S
64. Miller A.A., Hislop A.A., Vallance P.J., and Haworth S.G. Deletion of the eNOS gene has a greater impact on the pulmonary circulation of male than female mice. Am. J. Physiol., Lung Cell. Mol. Physiol. 289 (2005) L299-L306
65. Morecroft I., Loughlin L., Nilsen M., Colston J., Dempsie Y., Sheward J., Harmar A., and MacLean M.R. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J. Pharmacol. Exp. Ther. 313 (2005) 539-548
66. Morita K., Ihnken K., Buckberg G.D., Sherman M.P., and Ignarro L.J. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann. Thorac. Surg. 61 (1996) 1775-1780
67. Morris W., and Knauer C.M. Cardiopulmonary manifestations of schistosomiasis. Semin. Respir. Infect. 12 (1997) 159-170
68. Murata T., Sato K., Hori M., Ozaki H., and Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J. Biol. Chem. 277 (2002) 44085-44092
69. Newman J.H., Wheeler L., Lane K.B., Loyd E., Gaddipati R., Phillips III J.A., and Loyd J.E. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N. Engl. J. Med. 345 (2001) 319-324
70. Newman J.H., Trembath R.C., Morse J.A., Grunig E., Loyd J.E., Adnot S., Coccolo F., Ventura C., Phillips III J.A., Knowles J.A., Janssen B., Eickelberg O., Eddahibi S., Herve P., Nichols W.C., and Elliott G. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J. Am. Coll. Cardiol. 43 (2004) 33S-39S
71. Nieuw Amerongen G.P., and van Hinsbergh V.W. Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vasc. Pharmacol. 39 (2002) 257-272
72. Noguchi Y., Hislop A.A., and Haworth S.G. Influence of hypoxia on endothelin-1 binding sites in neonatal porcine pulmonary vasculature. Am. J. Physiol. 272 (1997) H669-H678
73. Pierce C.M., Krywawych S., and Petros A.J. Asymmetric dimethyl arginine and symmetric dimethyl arginine levels in infants with persistent pulmonary hypertension of the newborn. Pediatr. Crit. Care Med. 5 (2004) 517-520
74. Reddy V.M., Wong J., Liddicoat J.R., Johengen M., Chang R., and Fineman J.R. Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am. J. Physiol. 271 (1996) H562-H570
75. Resta T.C., Gonzales R.J., Dail W.G., Sanders T.C., and Walker B.R. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am. J. Physiol. 272 (1997) H806-H813
76. Reves J.G., Karp R.B., Buttner E.E., Tosone S., Smith L.R., Samuelson P.N., Kreusch G.R., and Oparil S. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation 66 (1982) 49-55
77. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Koerner S.K. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 107 (1987) 216-223
78. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., and Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 (2002) 896-903
79. Saidy K., and al Alaiyan S. The use of l-arginine [correction of F-arginine] and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Indian J. Pediatr. 68 (2001) 175-177
80. Shaul P.W. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 64 (2002) 749-774
81. Shaul P.W., Pace M.C., Chen Z., and Brannon T.S. Developmental changes in prostacyclin synthesis are conserved in cultured pulmonary endothelium and vascular smooth muscle. Am. J. Respir. Cell Mol. Biol. 20 (1999) 113-121
82. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., Gibbs S., Lebrec D., Speich R., Beghetti M., Rich S., and Fishman A. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43 (2004) 5S-12S
83. Sitbon O., Badesch D.B., Channick R.N., Frost A., Robbins I.M., Simonneau G., Tapson V.F., and Rubin L.J. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124 (2003) 247-254
84. Stiebellehner L., Belknap J.K., Ensley B., Tucker A., Orton E.C., Reeves J.T., and Stenmark K.R. Lung endothelial cell proliferation in normal and pulmonary hypertensive neonatal calves. Am. J. Physiol. 275 (1998) L593-L600
85. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J., Wheeler L., Higenbottam T., Gibbs J.S., Egan J., Crozier A., Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C., and Nichols W.C. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J. Med. Genet. 37 (2000) 741-745
86. Tulloh R.M., Hislop A.A., Boels P.J., Deutsch J., and Haworth S.G. Chronic hypoxia inhibits postnatal maturation of porcine intrapulmonary artery relaxation. Am. J. Physiol. 272 (1997) H2436-H2445
87. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1023-1030
88. Vosatka R.J., Kashyap S., and Trifiletti R.R. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. Biol. Neonate 66 (1994) 65-70
89. Wojciak-Stothard B., Tsang L.Y., and Haworth S.G. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am. J. Physiol., Lung Cell. Mol. Physiol. 288 (2005) L749-L760
90. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br. Med. J. 46 (1958) 755-762
91. Yan S.F., Ogawa S., Stern D.M., and Pinsky D.J. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int. 51 (1997) 419-425
92. Zenge J.P., Rairigh R.L., Grover T.R., Storme L., Parker T.A., Kinsella J.P., and Abman S.H. NO and prostaglandin interactions during hemodynamic stress in the fetal ovine pulmonary circulation. Am. J. Physiol., Lung Cell. Mol. Physiol. 281 (2001) L1157-L1163